A variety of patient, treatment, and pathologic factors have been reported to be associated with an increased risk of ipsilateral breast tumor recurrence after breast conservation therapy (BCT) for ...

Male breast cancer: Looking for prognostic subgroups. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does not include a full text component.

Choosing between a mastectomy and a lumpectomy? Learn the differences in survival rates, recovery times, and common misconceptions to find the right breast cancer surgery for you.

Despite evidence that use of adjuvant radiation therapy (RT) after lumpectomy yields no survival benefit for elderly women (aged 70 years and older) with small, estrogen-receptor-positive (ER+) breast ...

Patients with ductal carcinoma in situ (DCIS) are often treated with radiation after lumpectomy, although it has remained unclear whether this can reduce the risk of dying from this noninvasive form ...

“You know that phrase, ‘third time’s the charm?’ ” Marilene Nevins asks. Well, not always. In 1997, a suspicious mass was found in Nevins’ right breast. “I nicknamed that one Mickey,” she says. “You ...

For those with localized breast cancer, surgical options may include either lumpectomy or mastectomy, and patients have free rein about which to choose. Star Mackenzie Burruto had just gotten off the ...

The FDA approved pegulicianine (LumiSight) as an optical imaging agent for detecting residual cancer after breast-conserving surgery (BCS). The approval stipulates use of pegulicianine with the ...

Add Yahoo as a preferred source to see more of our stories on Google. Your doctor should explain in detail the approach he or she takes when performing a lumpectomy, but the process for removing a ...

Lumpectomy is the gold standard for breast cancer surgery, says Kirstyn E. Brownson, MD, a surgical breast oncologist at Huntsman Cancer Institute. We asked Dr. Brownson to explain what a lumpectomy ...

Approval was supported by data from a randomized, intra-patient controlled trial, which included patients with confirmed invasive breast cancer, ductal carcinoma in situ, or both. The Food and Drug ...